Literature DB >> 22441700

Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.

Baomei Shao1, Robert S Munford, Richard Kitchens, Alan W Varley.   

Abstract

Much evidence indicates that bacterial LPS (endotoxin) is removed from the bloodstream mainly by the liver, yet the hepatic uptake mechanisms remain uncertain and controversial. In plasma, LPS can be either 'free' (as aggregates, bacterial membrane fragments or loosely bound to albumin, CD14, or other proteins) or 'bound' (complexed with lipoproteins). Whereas most free LPS is taken up by Kupffer cells (KCs), lipoprotein-bound LPS has seemed to be cleared principally by hepatocytes. Here, we compared the liver's ability to take up and deacylate free LPS aggregates and the LPS in preformed LPS-high density lipoprotein (HDL) complexes. In mice examined from 1 h to 7 d after a small amount of fluorescent (FITC-)LPS was injected into a lateral tail vein, we found FITC-LPS almost entirely within, or adjacent to, KCs. As expected, FITC-LPS complexed with HDL (FITC-LPS-HDL) disappeared more slowly from the circulation and a smaller fraction of the injected dose of FITC-LPS was found in the liver. Unexpectedly, the FITC-LPS injected as FITC-LPS-HDL complexes was also found within sinusoids, adjacent to, or within, KCs. In other experiments, we found that both free and HDL-bound radiolabeled LPS underwent enzymatic deacylation by acyloxyacyl hydrolase (AOAH), the LPS-inactivating enzyme that is principally produced within the liver by KCs. Our observations suggest that KCs and AOAH play important roles in clearing and catabolizing both free LPS and the LPS in circulating LPS-HDL complexes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441700      PMCID: PMC4120711          DOI: 10.1177/1753425912442431

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  46 in total

Review 1.  Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines.

Authors:  Andrew M Miller; Norio Horiguchi; Won-Il Jeong; Svetlana Radaeva; Bin Gao
Journal:  Alcohol Clin Exp Res       Date:  2011-02-01       Impact factor: 3.455

Review 2.  Alcoholic liver disease and the gut-liver axis.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

3.  A role for intestinal alkaline phosphatase in the maintenance of local gut immunity.

Authors:  Kathryn T Chen; Madhu S Malo; Laura Kline Beasley-Topliffe; Klaas Poelstra; Jose Luis Millan; Golam Mostafa; Sayeda N Alam; Sundaram Ramasamy; H Shaw Warren; Elizabeth L Hohmann; Richard A Hodin
Journal:  Dig Dis Sci       Date:  2010-09-16       Impact factor: 3.199

4.  Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism.

Authors:  Melanie J Scott; Shubing Liu; Richard A Shapiro; Yoram Vodovotz; Timothy R Billiar
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  Chylomicrons promote intestinal absorption of lipopolysaccharides.

Authors:  Sarbani Ghoshal; Jassir Witta; Jian Zhong; Willem de Villiers; Erik Eckhardt
Journal:  J Lipid Res       Date:  2008-09-24       Impact factor: 5.922

6.  Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes.

Authors:  Melanie J Scott; Timothy R Billiar
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

Review 7.  Chapter 2: Kill the bacteria...and also their messengers?

Authors:  Robert Munford; Mingfang Lu; Alan Varley
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

8.  Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.

Authors:  Patrice D Cani; Rodrigo Bibiloni; Claude Knauf; Aurélie Waget; Audrey M Neyrinck; Nathalie M Delzenne; Rémy Burcelin
Journal:  Diabetes       Date:  2008-02-27       Impact factor: 9.461

9.  Host inactivation of bacterial lipopolysaccharide prevents prolonged tolerance following gram-negative bacterial infection.

Authors:  Mingfang Lu; Alan W Varley; Shoichiro Ohta; John Hardwick; Robert S Munford
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

10.  Stimulus-dependent deacylation of bacterial lipopolysaccharide by dendritic cells.

Authors:  Mingfang Lu; Mei Zhang; Richard L Kitchens; Susan Fosmire; Akira Takashima; Robert S Munford
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  24 in total

Review 1.  Endotoxemia-menace, marker, or mistake?

Authors:  Robert S Munford
Journal:  J Leukoc Biol       Date:  2016-07-14       Impact factor: 4.962

Review 2.  Novel insights in preventing Gram-negative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis of the immune system.

Authors:  Dong Xu; Manzhi Zhao; Yuhu Song; Jianxin Song; Yuancheng Huang; Junshuai Wang
Journal:  Hepatol Int       Date:  2014-11-21       Impact factor: 6.047

Review 3.  The role of the liver in sepsis.

Authors:  Jun Yan; Song Li; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-03-10       Impact factor: 5.311

4.  Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density Lipoprotein.

Authors:  Zhili Yao; Jessica M Mates; Alana M Cheplowitz; Lindsay P Hammer; Andrei Maiseyeu; Gary S Phillips; Mark D Wewers; Murugesan V S Rajaram; John M Robinson; Clark L Anderson; Latha P Ganesan
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

5.  Enterically derived high-density lipoprotein restrains liver injury through the portal vein.

Authors:  Yong-Hyun Han; Emily J Onufer; Li-Hao Huang; Robert W Sprung; W Sean Davidson; Rafael S Czepielewski; Mary Wohltmann; Mary G Sorci-Thomas; Brad W Warner; Gwendalyn J Randolph
Journal:  Science       Date:  2021-07-23       Impact factor: 47.728

Review 6.  Recent advances in nanomedicine for sepsis treatment.

Authors:  Simseok A Yuk; Diego A Sanchez-Rodriguez; Michael D Tsifansky; Yoon Yeo
Journal:  Ther Deliv       Date:  2018-05-01

7.  Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis.

Authors:  Meihong Deng; Melanie J Scott; Patricia Loughran; Gregory Gibson; Chhinder Sodhi; Simon Watkins; David Hackam; Timothy R Billiar
Journal:  J Immunol       Date:  2013-04-05       Impact factor: 5.422

Review 8.  Therapeutic interventions in sepsis: current and anticipated pharmacological agents.

Authors:  Prashant Shukla; G Madhava Rao; Gitu Pandey; Shweta Sharma; Naresh Mittapelly; Ranjita Shegokar; Prabhat Ranjan Mishra
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 9.  Gut-liver axis and sterile signals in the development of alcoholic liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Alcohol Alcohol       Date:  2017-07-01       Impact factor: 2.826

10.  Persistently active microbial molecules prolong innate immune tolerance in vivo.

Authors:  Mingfang Lu; Alan W Varley; Robert S Munford
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.